Davide Frumento

Biography:

He started his postdoctoral research under the mentorship of Prof. Paolo Fiorina at Biosciences Department, University of Milan (Milan, Italy), in collaboration with Nephrology Division, Boston Children’s Hospital, Harvard Medical School (MA, USA). He earned first-authorship and co-authorship statuses on the resultant peer-reviewed papers. His work in research continued under the guidance of Prof. Claudio Viscoli at the Health Sciences Department, University of Genoa (Genoa, Italy),
conducting research about antiretrovirals compliance in HIV patients and new generation anti-HCV drugs efficacy. He also have been appointed as a Coordinator for a clinical trial titled “Safety, tolerability & efficacy on LDL-C of Evolocumab in subjects with HIV & hyperlipidemia/mixed dyslipidemia” (Amgen Inc. 20130286 - AMG286 trial). He continued his work under the guidance of Prof. Santina Bruzzone at the Department of Experimental Medicine, University of Genoa (Genoa, Italy), investigating the onset delay effect of SIRT6 inhibition on in vitro/in vivo Multiple Sclerosis models, earning a co-authorship in the resultant peer-review article. He then conducted research on anti-influenza and anti-meningococcal vaccination strategy under the guidance of Prof. Donatella Panatto at Health Sciences Department, University of Genoa (Genoa, Italy), earning a co-authorship in the resultant peer-review articles [4,5]. He was then employed at the Department of Pharmacy, University of Genoa (Genoa, Italy), under the mentorship of Prof. Silvia Schenone, working on Organic Synthesis research, characterizing pyrazolo[3,4-d] pyrimidine tyrosine kinase inhibitors (TKIs). He published a work about it. Later, he was appointed as Adjunct Professor in Epigenetics at the Education Sciences Department, RomaTre University (Rome, Italy), lecturing post-graduate students and working on generational trauma along with Prof. Matteo Villanova. Such research work resulted in a research article as a first author.